Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShiji WangNorth China Electric Power University

Discussion

Loading...

Member takes

Overview

Meta-analysis demonstrates that CAR-T cell therapy shows higher efficacy than bispecific antibodies in relapsed B-NHL, suggesting distinct safety profiles.

Key Points

  • This research aims to systematically compare the efficacy and safety of CAR-T cell therapy and bispecific antibodies in treating relapsed B-cell non-Hodgkin lymphoma.
  • Conducted a systematic search for clinical trials
  • Performed a random-effects single-arm meta-analysis
  • Included 59 clinical trials with 2,914 patients
  • CAR-T cell therapy had an objective response rate of 72% compared to 50% for bispecific antibodies.
  • CAR-T therapy had a complete response rate of 54%, while bispecific antibodies had 33%.
  • Grade ≥3 adverse events were more common in the CAR-T group, including cytokine release syndrome and neurotoxicity.

Cite This Study

Shiji Wang (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236def0https://doi.org/10.1182/blood-2025-3741
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma2026
  2. 2CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis2025
  3. 3Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025
  4. 4Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025
  5. 5Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025